SG11202101970UA - Method for producing an antitumoral arenavirus as well as arenavirus mutants - Google Patents

Method for producing an antitumoral arenavirus as well as arenavirus mutants

Info

Publication number
SG11202101970UA
SG11202101970UA SG11202101970UA SG11202101970UA SG11202101970UA SG 11202101970U A SG11202101970U A SG 11202101970UA SG 11202101970U A SG11202101970U A SG 11202101970UA SG 11202101970U A SG11202101970U A SG 11202101970UA SG 11202101970U A SG11202101970U A SG 11202101970UA
Authority
SG
Singapore
Prior art keywords
arenavirus
antitumoral
mutants
producing
well
Prior art date
Application number
SG11202101970UA
Inventor
Karl Lang
Cornelia Hardt
Michael Bergerhausen
Hilal Bhat
Original Assignee
Abalos Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Therapeutics Gmbh filed Critical Abalos Therapeutics Gmbh
Publication of SG11202101970UA publication Critical patent/SG11202101970UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10051Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10051Methods of production or purification of viral material
    • C12N2760/10052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202101970UA 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants SG11202101970UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (en) 2018-09-12 2018-09-12 Process for the production of an antitumoral arenavirus and arenavirus mutants
PCT/EP2019/074307 WO2020053324A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Publications (1)

Publication Number Publication Date
SG11202101970UA true SG11202101970UA (en) 2021-03-30

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101970UA SG11202101970UA (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Country Status (17)

Country Link
EP (2) EP3694868B1 (en)
JP (1) JP2022500054A (en)
KR (1) KR20210057782A (en)
CN (1) CN112996802A (en)
AU (1) AU2019340845A1 (en)
BR (1) BR112021004451A2 (en)
CA (1) CA3111305A1 (en)
CL (1) CL2021000592A1 (en)
DE (1) DE102018215551A1 (en)
DK (1) DK3694868T3 (en)
ES (1) ES2908854T3 (en)
IL (1) IL281299A (en)
MX (1) MX2021002937A (en)
PH (1) PH12021550424A1 (en)
SG (1) SG11202101970UA (en)
WO (1) WO2020053324A1 (en)
ZA (1) ZA202101833B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024508823A (en) 2021-02-26 2024-02-28 アバロス セラピューティクス ゲーエムベーハー Novel viral particles for therapeutic purposes
CN117867030A (en) * 2024-01-15 2024-04-12 苏州健雄职业技术学院 Construction and application of stable cell line of mouse lung cancer cell line CMT167 luciferase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (en) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gene Therapy of Solid Tumors by Retroviral Arenavirus Glycoprotein-Pseudotyped Vectors
SI2604695T1 (en) 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replication-defective arenavirus vectors
US8785173B2 (en) * 2008-09-24 2014-07-22 Medimmune, Llc Methods for purification of viruses
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
US20150307559A1 (en) * 2012-12-12 2015-10-29 Children's Hospital Of Eastern Ontario Research Intitute Inc. Compositions and methods for the treatment of brain cancers
DE102015207036A1 (en) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviruses for use in the treatment and / or prevention of tumors, and methods of producing arenaviruses with (improved) tumor-regressive properties
CA3039356A1 (en) * 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Also Published As

Publication number Publication date
CA3111305A1 (en) 2020-03-19
EP3694868A1 (en) 2020-08-19
EP3694868B1 (en) 2021-11-03
ZA202101833B (en) 2022-10-26
DK3694868T3 (en) 2022-02-07
WO2020053324A1 (en) 2020-03-19
CL2021000592A1 (en) 2021-09-10
DE102018215551A1 (en) 2020-03-12
KR20210057782A (en) 2021-05-21
IL281299A (en) 2021-04-29
EP4019533A1 (en) 2022-06-29
AU2019340845A1 (en) 2021-05-06
CN112996802A (en) 2021-06-18
JP2022500054A (en) 2022-01-04
MX2021002937A (en) 2021-07-16
US20220033445A1 (en) 2022-02-03
ES2908854T3 (en) 2022-05-04
PH12021550424A1 (en) 2021-09-20
BR112021004451A2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
IL276597A (en) Method for producing low-antigenic cell
HUE064016T2 (en) Method for producing lgps-based solid electrolyte
EP3792237A4 (en) Method for producing fluoroolefin
EP3991184C0 (en) Method for producing 225actinium from 226radium
EP3598462A4 (en) Method for producing solid electrolyte
SG11202002498SA (en) Method of producing an electrocatalyst
EP3763747A4 (en) Method for producing fluoropolymer
EP4063403A4 (en) Method for producing fluoropolymer
EP3747624A4 (en) Method for producing structure
ZA202101833B (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
GB201819928D0 (en) Method for generating persulfate
EP3828252C0 (en) Method for producing biofuel
EP3831804A4 (en) Method for producing 1-acyloxy-2-methyl-2-propene
PL3733651T3 (en) Method for producing calcobutrol
IL287063A (en) Method for producing biotissue-like structure
EP3675246A4 (en) Method for producing anode and anode produced therefrom
EP3751643A4 (en) Method for producing positive electrode
SG11202106891PA (en) Method for producing cyclobutene
EP3860823C0 (en) Method for producing an elastomeric skin
EP3882342A4 (en) Method for producing brain organoids
EP3778687A4 (en) Method for producing polymerizable composition
EP3778560A4 (en) Method for producing acrylonitrile
HUE061957T2 (en) Method for producing cathode particles
EP3604563A4 (en) Method for producing rail
EP4068424A4 (en) Method for producing electrode